Salmeterol
- Generic Name
- Salmeterol
- Brand Names
- Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 89365-50-4
- Unique Ingredient Identifier
- 2I4BC502BT
- Background
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.
Salmeterol was granted FDA approval on 4 February 1994.
- Indication
用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Tiotropium/Salmeterol (T+S_PE)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 147
- Registration Number
- NCT00662792
- Locations
- 🇩🇪
1184.13.1312 Boehringer Ingelheim Investigational Site, Hamburg, Germany
🇩🇪1184.13.1305 Boehringer Ingelheim Investigational Site, Mainz, Germany
🇩🇪1184.13.1301 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 57
- Registration Number
- NCT00640484
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT00622635
- Locations
- 🇪🇸
Novartis Investigator site, Mataro, Spain
🇪🇸Novartis Investigator Site, Madrid, Spain
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 96
- Registration Number
- NCT00615030
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Spain
Dose Finding Study of CHF 4226 for Treating Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 278
- Registration Number
- NCT00605891
- Locations
- 🇨🇿
Ordinace pro nemoci dychaciho ustroji, Beroun, Czech Republic
🇺🇸University Clinical Research - DeLand, LLC, DeLand, Florida, United States
🇵🇱NZOZ Non-nocere, Gdansk, Poland
How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00595361
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange
- Conditions
- COPD
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Arthur F Gelb MD
- Target Recruit Count
- 39
- Registration Number
- NCT00568347
- Locations
- 🇺🇸
Arthur F Gelb MD, Lakewood, California, United States
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1002
- Registration Number
- NCT00567996
- Locations
- 🇫🇷
Novartis Investgative Site, Ferolles-Attilly, France
🇮🇹Novartis investigator site, Chieti, Italy
🇮🇹Novartis Investigative Site, Ascoli Piceno, Italy
Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 210
- Registration Number
- NCT00565266
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Columbia University Health Sciences, New York, New York, United States
🇺🇸University of California, San Diego, San Diego, California, United States
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7376
- Registration Number
- NCT00563381
- Locations
- 🇦🇹
205.389.1020 Boehringer Ingelheim Investigational Site, Feldbach, Austria
🇦🇹205.389.1002 Boehringer Ingelheim Investigational Site, Wien, Austria
🇨🇿205.389.1204 Boehringer Ingelheim Investigational Site, Brno-Kralovo Pole, Czech Republic
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.